Max Fehlmann

Chronogen, Inc. develops drugs to treat age-dependent diseases. It manufactures drugs for neurodegenerative, cardiovascular, ischemia and reperfusion injury, and dyslipidemia diseases. The company was founded by Siegfried Hekimi in April 1998 and is headquartered in Montréal, Canada

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Institut de recherches cliniques de Montréal operates as an independent non-profit research institution focusing on biomedical research. The firm excels in basic research of economic development in the fields of pharmaceuticals, biotechnology and health services. The company was founded in 1967 and is headquartered in Montr?al, Canada.

The Cancer Research Society is a non-profit organization that focuses on cancer research. The organization is based in Montreal, Canada. The organization has received support from Stéphane Rousseau, who is a spokesperson for the organization and actively supports their efforts. Max Fehlmann has been the CEO of the Canadian company since 2017.

Neomed Institute operated as a non-profit organization for pharmaceutical companies. It offered analytical services, drug development, licensing, and drug discovery. The company was founded in 2012 and was headquartered in Montreal, Canada.

Consortium Québécois sur la Découverte du Médicament (CQDM) is a not-for-profit biopharmaceutical research consortium based in Montréal, Canada. CQDM's mission is to support and facilitate multi-stakeholder collaborative R&D aimed at accelerating the translation of innovative technologies into solutions that address unmet medical needs, while generating significant benefits for the Quebec and Canadian economy. CQDM funds the development of innovative tools and technologies that accelerate the discovery and development of safer and more effective drugs. The company's Quantum Leap pharma-led funding program for drug discovery research helps SMEs or Canadian universities achieve innovative translational biopharmaceutical research projects. CQDM's SynergiQC-International program is designed to promote university-based industrial research in the biopharmaceutical field with collaborators outside, that will generate economic benefits. The non-profit company was founded by Max Fehlmann.

NEOMED-LABS, Inc. engages in operation of a contract research organization. It offers clinical immunology laboratory services. The company was founded by Max Fehlmann in March 4, 2015 and is headquartered in Montréal, Canada.

Zambon Co. SpA operates as an industrial holding company with interests in pharmaceuticals and chemicals. The company was founded by Gaetano Zambon on November 11, 1906 and is headquartered in Bresso, Italy.